VolitionRx Ltd (NYSEMKT:VNRX), the developer of blood-based tests that check for cancer, has begun a two-phase logistical study of Nu.Q diagnostic test.
The two-phase logistical study, focused on colorectal cancer screening, is being conducted in collaboration with Hvidovre Hospital and the Danish Research Group on Early Detection of Colorectal Cancer.
VolitionRX said it expects both phases of the study are expected to be completed within six months.
The aim of the first phase is to evaluate the logistics in collecting and processing blood samples at a local screening center and subsequently shipping the samples to a central laboratory in Denmark to run the Nu.Q analysis.
This phase is expected to be completed within two months.
The second phase will assess the time taken between blood collection, analysis and results.
When added to the existing clinical data previously announced, this logistics study aims to complete the information needed to add VolitionRX’s test to the national screening program.
“We have been impressed with the preliminary clinical data of the Nu.Q colorectal cancer screening triage test and the potential to reduce unnecessary colonoscopies,” said Morten Rasmussen, head of the colorectal screening program in the Capital Region of Denmark.
“Before introducing any such test into the Danish National Screening program, we need to determine the very practical logistics of putting into practice Volition’s Nu.Q triage test to ensure a smooth, patient-friendly, and efficient implementation of our screening programme,” Dr Rasmussen added.
VolitionRX’s chief executive, Cameron Reynolds, said the studies marked an important milestone in the commercialization of the company’s flagship product.
“We have had a long, mutually beneficial relationship with our collaborators in Denmark and are very pleased that this logistics study will be undertaken to answer key issues to make sure any potential roll-out nationally would be smooth. We also envisage this study will assist other countries in assessing the implementation of the Nu.Q Triage Test within their national screening programs,” Reynolds said.
Story by ProactiveInvestors